Cassin Kimmel Williams
Research Subjects
Research Interests
Cassin Kimmel Williams has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alicia Gunning
Naveris, Inc., Waltham, MA 02451, USA
1 shared publication - Barry M. Berger
Naveris, Waltham, MA 02451, USA
1 shared publication - Catherine Del Vecchio Fitz
Naveris, Inc., Natick, Massachusetts
1 shared publication - Charlotte Kuperwasser
Naveris, Inc., Waltham, MA 02451, USA
1 shared publication - Piyush B. Gupta
Naveris, Inc., Waltham, MA 02451, USA
1 shared publication - Stephen P. Naber
Naveris, Inc., Waltham, MA 02451, USA
1 shared publication
Latest Publications
- Open Access
- 14 February 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (4) , 725
Analytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers
The NavDx® blood test analyzes tumor tissue modified viral (TTMV)-HPV DNA to provide a reliable means of detecting and monitoring HPV-driven cancers. The test has been clinically validated in a large number of independent studies and has been integrated into clinical practice by over 1000 healthcare providers at over 400 medical sites in the US. This Clinical Laboratory Improvement Amendments (CLIA), high complexity laboratory developed test, has also been accredited by the College of American Pathologists (CAP) and the New York State Department of Health. Here, we report a detailed analytical validation of the NavDx assay, including sample stability, specificity as measured by limits of blank (LOBs), and sensitivity illustrated via limits of detection and quantitation (LODs and LOQs). LOBs were 0–0.32 copies/μL, LODs were 0–1.10 copies/μL, and LOQs were 2 = 1) across a broad range of analyte concentrations. These results demonstrate that NavDx accurately and reproducibly detects circulating TTMV-HPV DNA, which has been shown to aid in the diagnosis and surveillance of HPV-driven cancers.
- 14 February 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (4) , 725
Open AccessAnalytical Validation of NavDx, a cfDNA-Based Fragmentomic Profiling Assay for HPV-Driven Cancers
The NavDx® blood test analyzes tumor tissue modified viral (TTMV)-HPV DNA to provide a reliable means of detecting and monitoring HPV-driven cancers. The test has been clinically validated in a large number of independent studies and has been integrated into clinical practice by over 1000 healthcare providers at over 400 medical sites in the US. This Clinical Laboratory Improvement Amendments (CLIA), high complexity laboratory developed test, has also been accredited by the College of American Pathologists (CAP) and the New York State Department of Health. Here, we report a detailed analytical validation of the NavDx assay, including sample stability, specificity as measured by limits of blank (LOBs), and sensitivity illustrated via limits of detection and quantitation (LODs and LOQs). LOBs were 0–0.32 copies/μL, LODs were 0–1.10 copies/μL, and LOQs were 2 = 1) across a broad range of analyte concentrations. These results demonstrate that NavDx accurately and reproducibly detects circulating TTMV-HPV DNA, which has been shown to aid in the diagnosis and surveillance of HPV-driven cancers.